Artelo Biosciences
United States
About Artelo Biosciences
96 articles about Artelo Biosciences
-
Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge
3/12/2024
Artelo Biosciences, Inc. today announced its selection as a finalist in Johnson & Johnson’s Innovation Challenge.
-
Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12’s Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy
1/23/2024
Artelo Biosciences, Inc. today announced new research published in the peer-reviewed Journal of Pain.
-
Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12
1/8/2024
Artelo Biosciences, Inc. today announced that it has selected Worldwide Clinical Trials to support the Company’s planned Phase 1 trial with ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor in development for the treatment of chemotherapy-induced peripheral neuropathy (CIPN).
-
Artelo Biosciences Presents New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany
12/5/2023
Artelo Biosciences, Inc. today announced new preclinical data on ART12.11, the Company’s proprietary cocrystal of cannabidiol (CBD) and tetramethylpyrazine (TMP), was presented at the 4th Annual Med-Cannabis 2023 conference today, December 5, 2023.
-
Artelo Biosciences to Present Important New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany
11/30/2023
Artelo Biosciences, Inc. today announced George Warren, PhD., Principal Scientist at Artelo Biosciences, will be presenting new preclinical data on ART12.11.
-
Artelo Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update
11/13/2023
Artelo Biosciences, Inc. today reported financial and operating results for the three months ended September 30, 2023 and provided a business update.
-
Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating Protective Properties of ART27.13 Against Muscle Degeneration Caused by Certain Cancers
11/9/2023
Artelo Biosciences, Inc. announced new research published in the peer-reviewed journal Pharmaceuticals.
-
Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023
11/2/2023
Artelo Biosciences, Inc. today announced that the research group working with Steven Laviolette, Ph.D., Scientific Advisor at Artelo Biosciences and Professor in the Schulich School of Medicine at the University of Western Ontario, Canada, will be presenting at Neuroscience 2023.
-
Principal Investigator of Artelo’s CAReS Trial to Participate in Medical Expert Webinar Hosted by H.C. Wainwright to Discuss Current Development Strategies for Cancer-Related Anorexia and Cachexia
10/4/2023
Artelo Biosciences, Inc. announced that H.C. Wainwright will be hosting a virtual medical expert webinar on October 11, 2023 at 12:00 p.m. Eastern Time to discuss the current treatment landscape for cancer-related anorexia and cachexia.
-
Artelo Biosciences to Present at the 13th Congress of the European Pain Federation on September 20th
9/13/2023
Artelo Biosciences, Inc. today announced that Professor Saoirse O’Sullivan, Artelo’s Vice President of Translational Sciences, will be presenting at the 13th Congress of the European Pain Federation (EFIC) being held September 20-22, 2023.
-
Artelo Biosciences Completes Positive Pre-IND Meeting with FDA for ART26.12Announces Plans to File IND Application in Neuropathic Pain
9/7/2023
Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced it has completed a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the manufacturing, preclinical and clinical development plan for ART26.12.
-
Artelo Biosciences to Present at the 6th Cannabinoid-Derived Drug Development Summit on September 12th
9/6/2023
Artelo Biosciences, Inc. (Nasdaq: ARTL) Medicinal Chemist at Artelo Biosciences, will be presenting at the 6th Cannabinoid-Derived Drug Development Summit being held September 11-13, 2023 at the Hilton Boston Back Bay hotel in Boston, MA.
-
Artelo Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 13th
9/5/2023
Artelo Biosciences, Inc. (Nasdaq: ARTL) today announced that it will be participating in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 at the Lotte New York Palace Hotel in New York City.
-
Artelo Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update
8/10/2023
Artelo Biosciences, Inc. reported financial and operating results for the three months ended June 30, 2023 and provided a business update.
-
Artelo Biosciences CEO to Participate in the Benzinga All Access Event on July 11
7/10/2023
Artelo Biosciences, Inc. today announced that Gregory D. Gorgas, President & Chief Executive Officer of Artelo Biosciences, will be participating in the Benzinga All Access event taking place on Tuesday, July 11, 2023.
-
Artelo Biosciences Announces Sponsorship of The William A. Devane Early Career Investigator Award at the 33rd Annual International Cannabinoid Research Society Symposium
6/28/2023
Artelo Biosciences, Inc. today announced its continued sponsorship of The William A. Devane Early Career Investigator Award at the 33rd International Cannabinoid Research Society (ICRS) Symposium in Toronto, Ontario, Canada.
-
Artelo Biosciences Announces Important New Data on ART26.12 Demonstrating Positive Effects in Multiple Models of Neuropathic Pain at the 33rd Annual International Cannabinoid Research Society Symposium
6/27/2023
Artelo Biosciences, Inc. announced that Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo, presented preclinical data related to ART26.12, Artelo’s novel fatty acid binding protein 5 (FABP5) inhibitor at the 33rd International Cannabinoid Research Society (ICRS) Symposium in Toronto, Ontario, Canada.
-
Artelo Biosciences Reports Superior Preclinical Pharmaceutical Properties and Efficacy of ART12.11 Compared to Cannabidiol (CBD) at the 33rd Annual International Cannabinoid Research Society Symposium
6/26/2023
Artelo Biosciences, Inc. announced that Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo, presented important new data from multiple preclinical studies regarding ART12.11, Artelo’s patented cannabidiol (CBD) cocrystal, on Sunday, June 25th, at the 33rd International Cannabinoid Research Society (ICRS) Symposium in Toronto, Ontario, Canada.
-
Artelo Biosciences Selected for Oral Presentation to Report Positive Research Findings on ART12.11 at the 33rd Annual International Cannabinoid Research Society Symposium
6/7/2023
Artelo Biosciences, Inc. today announced that it was selected for an oral presentation at the 33rd International Cannabinoid Research Society (ICRS) Symposium being held on June 24-29, 2023 in Toronto, Ontario, Canada.
-
Artelo Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
5/11/2023
Artelo Biosciences, Inc. today reported financial and operating results for the three months ended March 31, 2023 and provided a business update.